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Maternal embryonic leucine zipper kinase (MELK) is a highly conserved serine/threonine kinase initially found to be
expressed in a wide range of early embryonic cellular stages, and as a result has been implicated in embryogenesis
and cell cycle control. Recent evidence has identified a broader spectrum of tissue expression pattern for this kinase
than previously appreciated. MELK is expressed in several human cancers and stem cell populations. Unique spatial
and temporal patterns of expression within these tissues suggest that MELK plays a prominent role in cell cycle
control, cell proliferation, apoptosis, cell migration, cell renewal, embryogenesis, oncogenesis, and cancer treatment
resistance and recurrence. These findings have important implications for our understanding of development,
disease, and cancer therapeutics. Furthermore understanding MELK signaling may elucidate an added dimension of
stem cell control.
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As a member of the AMPK/Snf1 family, Maternal Em-
bryonic Leucine-zipper Kinase (MELK) encodes a serine/
threonine kinase that is highly conserved across a variety
of mammalian and non-mammalian species. The MELK
gene was initially cloned from mice (Mus musculus) using
differential display analysis of cDNA libraries from un-
fertilized eggs and preimplantation embryos [1]. This ex-
periment identified MELK to be one of three uniquely
stored maternal mRNAs expressed in the developing egg
and embryo [1]. Due to the presence of a conserved
serine/threonine kinase domain in the N-terminal region,
MELK was classified as a novel member of the AMPK/
Snf1 family [1,2]. Similar to the other family members, the
catalytic domain of MELK is followed by a Ubiquitin-
Associated (UBA) domain, which is essential for its cata-
lytic activity [3,4]. The kinase activity of the other AMPK/
Snf1 family members is dependent on phosphorylation in
their activation loop by upstream kinases (such as LKB1
or CaMKK2). Interestingly, MELK is activated by auto-* Correspondence: ichiro.nakano@osumc.edu
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in any medium, provided the original work is pphoshorylation in vitro [5]: a unique mechanism among
the AMPK/Snf1 family members.
Shortly after the discovery of MELK in mouse egg and
preimplanation embryos, a second group cloned MELK—
also known as MPK38 (Murine protein serine/threonine
kinase 38)—from a murine teratocarcinoma cell line,
PCC4 [6]. The group went on to show a wide expres-
sion pattern in adult tissues, and found that MELK is
expressed in the thymus and spleen, but not present in
muscle, kidney, or liver. Interestingly, MELK expression
was restricted to T lineage cells and macrophage/mono-
cyte cells, but was not detectable in a B cell line [6]. MELK
was found to have active kinase catalytic activity in an
immune complex kinase assay, suggesting a functional
gene product was indeed formed in these tissues [6].
The authors postulated that MELK plays an important
role in signal transduction of certain lineages of hema-
topoietic cells.
Since those seminal discoveries, more groups have ex-
amined the expression patterns of MELK using different
organ systems and cell types, and across different species
in both normal and neoplastic cells. As a result, we have
a better understanding of some basic mechanisms, func-
tions, and signaling pathways involving MELK, including
interactions that link it with tumor progression. Thoughan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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studies are required to ascertain specific roles and path-
ways. Knockdown studies, using short hairpin RNAs
(shRNA) and small molecule inhibitors, and forced over-
expression studies have allowed for careful experiments
to unravel the precise cellular functions of MELK. These
studies, discussed in subsequent sections, have impli-
cated MELK in a number of cellular processes, and sug-
gest an important role for MELK in cancer biology.
The identification of the protein structure of human MELK
has enabled investigators to study MELK orthologs in various
species. The protein structure of MELK has been mainly con-
served across various mammalian and non-mammalian spe-
cies as depicted in Figure 1. Interestingly, the functional roles
of MELK appear to be slightly different in each species.
MELK orthologues in Xenopus laevis have been shown to
interact and phosphorylate key proteins to regulate G2/
M cell cycle progression [7]. As a result, MELK has
been strongly postulated to play a functional roll in cell
cycle regulation, proliferation, mitosis and spliceosome as-
sembly [8-11].
In non-mammalian systems such as Caenorhabditis elegans,
Danio rerio (zebra fish), and Xenopus, MELK plays an import-
ant role in cell division, as well as propagation and mainten-
ance of some organ-specific stem cells [12-14]. Likewise, in
mammalian systems, MELK is essential for organogenesis,
stem cell proliferation, and cell cycle regulation. Interestingly,
MELK is additionally involved in the development of numer-
ous human cancers, tumor initiation, and tumor propagation
[15-17]. Although recent studies have shed light on the con-
text-dependent, diverse physiological roles of MELK and its
involvement in various signaling pathways, MELK’s functions
and regulatory mechanisms are just starting to be understood.
Review
Cell cycle regulation: Pro-apoptotic and anti-apoptotic
functions of MELK
MELK’s expression patterns in mammalian and non-
mammalian systems, and its associations with cellularFigure 1 The domains essential for the kinase activity, namely the kin
the % of identical/conserved residues in the different domains (kinase + UB
601-651 in human MELK) for the different species compared to human Meproteins, cued scientists to explore its role in cell cycle
regulation. For example, MELK expression is restricted
to proliferating cells in early embryonic development,
and is expressed at particularly high levels in cancer
cells [10]. In addition, in the TC7 intestinal cancer cell
line, MELK expression levels cycle similarly to those of
cyclin A, cyclin B, and CDK4 [10]. In brain tumors,
MELK mRNA expression is co-regulated with that of
known mitosis-phase regulatory proteins such as ASPM
and Aurora Kinase B [18]. Thus the regulation and ex-
pression levels of MELK correlate with other kinases
and enzymes involved in cell cycle progression. These
data underscore a a prominent role for MELK regulating
cell cycle progression. In addition, depletion of MELK
with siRNA caused a G1/S phase cell cycle arrest in GBM
[17], suggesting MELK may even be required for cell cycle
progression. Notably, similar conclusions can be drawn
from data collected from nonmammalian systems. For
example, in Xenopus, the cycling of MELK depends
on its phosphorylation during M-phase, stabilizing it,
whereas dephosphorylation of MELK coincides with its
degradation [10].
It is important to note that MELK’s effect on promoting
or inhibiting apoptosis is still an area of active research, as
evidence for both of these roles exists. Jung et. al. showed
in mice, that MELK phosphorylates Apoptosis Signal-regu-
lating Kinase 1 (ASK1). This induces H2O2-mediated apop-
tosis in embryonic kidney and hematopoietic cells [19]. In
(HCT116) colon cancer cells, MELK interacts with p53,
and overexpression of MELK increases p53 expression pro-
portionately in vitro and in vivo [20]. MELK also phosphor-
ylates the Ser15 residue on p53 and stimulates its activity.
Importantly, this pro-apoptotic function of MELK is also
observed in some non-mammalian systems. For example,
MELK has a role in promoting apoptosis in C. elegans
through a caspase-independent cell extrusion method
(described later) [21]. Together, these studies suggest
MELK may have a critical role in promoting apoptosis
in developmental models and some forms of cancer.ase, UBA and KA1 domain are highlighted. The numbers indicate
A domain residues 11-326, variable domain 327-600, KA1 residues
lk (H. sapiens) as revealed by a Blast search.
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anti-apoptotic. In glioblastoma (GBM) cells, a highly ma-
lignant brain cancer, the expression of p53 exhibited an in-
verse correlation with MELK expression. MELK silencing
increased p53 expression and induced p53-dependent
apoptosis [22]. In HEK 293T cells, the promoter activity of
p53 diminished with MELK overexpression, whereas
knockdown of MELK with shRNA yielded the opposite re-
sult. Functionally, p53 inhibition partially rescued MELK
depletion-mediated GBM cell apoptosis. Given that MELK
and p53 appear to be exclusively expressed in glioma cells,
we proposed that MELK negatively regulates p53 activ-
ity and vise versa. We postulate that MELK has anti-
apoptotic actions through its regulation on p53. In
breast cancer models Lin et al. showed that the effect
of MELK on cancer cell growth is associated with re-
sistance to apoptosis through the inhibition of a pro-
apoptotic function of Bcl-G [23], although these results
are challenged by other studies [24].
It is possible that MELK may be involved in both pro-
and anti-apoptotic pathways indicating a possible context-
dependent function. Evidence for this possibility is the
paradoxical involvement of MELK in promoting cell div-
ision and also cell death in C. elegans [12,21]. Overall,
these studies support dual roles for MELK and continued
research will give us better understanding of the regulators
and biological contexts in which MELK is pro-apoptotic
and anti-apoptotic.
MELK in mammalian organ development and tissue
homeostasis
Members of the AMPK/Snf1 family in the mammalian
system are generally associated with cell survival under
conditions of nutrient starvation [25]. MELK appears to
regulate mitotic cell progression in early embryogenesis
[1], in somatic stem cells [15], and in certain cell line-
ages of the hematopoietic system [6].
MELK is preferentially expressed by immature cells in
the brain including neural stem cells (NSCs) throughout
mouse development [9]. Furthermore, NSCs depend on
MELK for their proliferation, thus implicating MELK in
mitotic progression and stem cell maintenance. In the
mouse central nervous system, MELK expression is res-
tricted to early and mid-embryonic developmental stages
and is absent in the adult brain [9]. In particular, MELK
mRNA is strongly expressed within periventricular ger-
minal zones, but is largely absent outside the germinal
zones suggesting that post-mitotic differentiated cells
lack MELK expression. This expression pattern is similar
to that observed with zMELK (zebrafish ortholog) [13],
supporting a conserved role for MELK in maintaining
stem/progenitor identity. MELK is also expressed in the
mouse postnatal hippocampus, which is the other region
where neural stem cells reside [9]. Neurosphere culturesderived from embryonic and postnatal subventricular zone
tissues demonstrate that forced MELK overexpression in-
creased the number of self-renewing neurosphere-forming
cells, whereas knockdown showed significant reduction.
Collectively, in the mouse brain, MELK is expressed by
neural stem cells and regulates their proliferation.
MELK in cancers and cancer stem cells
Preferential upregulation of MELK in cancers and recent
data from knockdown and forced overexpression studies
suggest that MELK promotes cancer cell growth. MELK
overexpression has been identified in several human
cancers: prostate [26], breast [27], brain [28], colorectal
[29] and gastric [8]. In glioblastoma (GBM), mRNA and
protein expression of MELK is highly unregulated, and
inversely correlates to patient post-surgical survival [28].
Increased MELK expression was detected in particularly
aggressive subtypes of breast cancer such as basal-like
breast cancer (BBC), and correlates with poor prognosis
[27,30]. Knockdown of MELK with shRNA (breast can-
cer cell line T-47D) resulted in decreased proliferation of
cells both in vitro and in vivo [27]. MELK knockdown
decreased proliferation and anchorage-independent growth
in vitro, and decreased tumor growth in vivo in breast,
pancreatic, and colorectal carcinomas [29]. These findings
suggest that MELK activity is implicated in tumor growth
and aggressiveness, and inhibition of MELK may be an at-
tractive cancer therapeutic target.
The isolation and characterization of cancer stem cells
(CSCs) from several types of primary cancers has pro-
vided a major paradigm shift in our understanding of
cancer biology [31]. The cancer stem cell hypothesis
postulates that tumor cells are hierarchically organized
with respect to tumor growth initiation and treatment
resistance. Furthermore, cancer stem cells represent a
subpopulation of cancer cells with tumor-initiating cap-
ability. These cells give rise to a variety of tumor cells in
response to cellular and environmental signals, and are
hypothesized to play a role in tumor initiation and
propagation [32]. Cancer stem cells have become a novel
and attractive therapeutic target because of the pivotal
role they play in treatment, resistance, and recurrence,
as they are a source of cell renewal within the tumor.
MELK has been shown to be differentially expressed
in cancer stem cells [16]. MELK knockdown by small
interfering RNA (siRNA) or short hairpin RNA (shRNA)
induced apoptosis of cancer stem cells in GBM stem
cells (GSCs) both in vitro and in vivo. In contrast, MELK
knockdown arrested proliferation of mouse neural pre-
cursors without causing a significant increase in cell
death, at least in vitro. Of note, MELK silencing in vivo
induced glial differentiation of GSCs resulting in less ag-
gressive, lower grade tumors. While MELK regulates
NSC and GSC proliferation, it likely only plays a role in
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makes MELK an attractive therapeutic target in GBM.
In colorectal carcinoma, MELK expression was elevated
when compared to normal tissues, andwas found to be spon-
taneously elevated in amurinemodel of intestinal tumorigen-
esis [29].MELK also localized to tumor cells and in particular
the basal regions of crypts of normal gastrointestinal epithe-
lium—the stem cell location in normal colonic tissue [29].
This finding suggestsMELK overexpressionmay be involved
in the malignant transformation of normal stem cells. In
addition, MELK is preferentially expressed in proliferating
cells in normalmammary gland luminal cells [33]. These cells
are thought to be the origin of mammary ductal tumors in
humans and mice [34]. This underscores the possibility that
MELK upregulation may be involved in tumor formation.
Conclusions derived from these studies suggest that MELK
provides a unique growth advantage in cancer, and that itmay
be doing so by playing an important inmaintaining the prop-
erties of the cancer stemcell population.
MELKmay also play an interesting role in tumor resistance
to therapies. In GBM and other High Grade Gliomas (HGG),
experimentalradiationtreatmentstronglyupregulatedMELK
invitro and invivo [22,35].This indicates thatMELK is likely a
stress-induced kinase. In addition, blockingMELK upregula-
tion in radiation-treated glioma stem cells (GSCs) with
shRNA-mediated silencing, and inhibition of MELK with a
small molecule kinase inhibitor C1 resulted in increasedFigure 2 This schematic highlights many of the signaling pathways M
progression and tumor formation. Since many mysteries still surround MEL
regulation and signaling pathways.cellular apoptosis.However,MELKoverexpressionpromoted
cancer cell growth [36]. Similar findings were observed in
models of colorectal cancer [37]. Treatment of the rectal can-
cer cell line SNU-503 with 5-flourouracil or radiation in-
creased MELK expression [37]. In addition, knockdown of
MELK with siRNA decreased cell proliferation and caused
changes in the cell cycle after radiation or 5-FU treatment.
These pharmacological data indicate that upregulation of
MELK contributes to the survival of tumor cells, particularly
when they suffer from radiation insult. Because the inhibition
ofMELKhas a greater effect on cancer stemcells thannormal
stemcells, thedevelopmentofnovelpharmaceutical therapies
that targetMELKisanactiveareaofclinical investigation.
Signaling mechanisms that mediate MELK action
Since the discovery of MELK, many signaling proteins
and pathways that regulate the action of MELK have been
discovered, some of which are highlighted in Figure 2.
Early biochemical analyses found that exogenously ex-
pressed murine MELK binds to the zinc-finger-like Zpr9,
which results in the activation of the oncogenic transcrip-
tion factor B-Myb in murine cell lines [38].
MELK both regulates and is regulated by one family of
MAP kinases, the c-Jun NH(2)-terminal kinases (JNKs)
in a cancer-specific manner [22]. The JNK pathway is re-
quired for the regulation of cell proliferation, apoptosis,
and inflammatory responses in cancers, including HGGs.ELK is involved in. Upregulation of MELK drives cell cycle
K, more factors will likely be discovered to play a role in MELK
Ganguly et al. Clinical and Translational Medicine  (2015) 4:11 Page 5 of 8Data indicate that MELK binds c-JUN, the downstream
oncogenic transcription factor target of JNK, in GSCs,
but not in normal progenitors. This binding of c-JUN to
MELK is diminished when the kinase activity of MELK
is nullified, suggesting that the kinase activity of MELK
is required for its interaction with c-JUN. Thus, the
tumor-specific MELK interaction with JNK/c-JUN is
likely one of the mechanisms for the selective apoptosis
that occurs as a result of MELK inhibition in GSCs, but
not in normal progenitors.
In cancer cells, MELK forms a protein complex with
the transcription factor/oncogene FOXM1, a master
regulator for cell cycle progression [35]. FOXM1 is over-
expressed in a number of human cancers including
GBM. MELK-regulated phosphorylation of FOXM1 fa-
cilitates FOXM1 transcriptional activity and induces the
expression of various mitotic regulators (e.g. Survivin,
Aurora B, and CDC25B). Based on the evidence that
FOXM1 directly interacts and is phosphorylated by
MELK in GSCs, MELK may orchestrate the priming
event of the complex signaling toward p53, VEGF, and
Wnt/β-catenin in cancers including GBM.
A target for therapy
Given the preferential upregulation of MELK in cancers
and recent experimental data suggesting the positive role
of MELK on cancer cell growth, MELK has been re-
cognized as a potential therapeutic target for brain, colo-
rectal, lung, and ovarian cancers [29]. In light of these
preclinical studies, novel therapeutics have been devel-
oped to selectively target MELK in cancers. As demon-
strated by Compound 1 (C1) and OTSSP167, discoveries
of novel Small Molecule Drugs (SMDs) that inhibit MELK
can be potential therapies for cancers with high levels of
MELK expression [36,39,40]. For example, OTSSP167
suppressed mammosphere formation of breast cancer
cells, and suppressed tumor growth in xenograft studies
of breast, lung, prostate, and pancreas cancer cell lines
in mice by both intravenous and oral administration
[41]. Currently, OTSSP167 is in a Phase I, single-center,
cohort dose escalation trial for patients with any locally
advanced or metastatic solid tumor malignancies re-
fractory to current treatments (clinicaltrials.gov identi-
fier: NCT01910545). This study, being conducted by
OncoTherapy Science Inc. at the University of Chicago
since August 2013, is the first human trial of a MELK
inhibitor. The final data collection for primary outcomes
is estimated to occur by December 2015, the results of
which are highly anticipated.
Role of MELK in neuroblast divisions in C. elegans
Much of our understanding of the functional roles, sig-
naling mechanisms, and structure of MELK comes from
findings in nonmammalian species. Orthologs of MELKhave been identified in a few species, and allow us to
study the role of MELK in developmental biology. PIG-1
is the MELK orthologue in C. elegans. As depicted in
Figure 1, a high degree of homology exists between the
N-terminal kinase domain (72%) and the C-terminal
KA1 domain (74%) of PIG-1 and mouse Melk, while the
remaining domains are much less conserved.
Physiologically, PIG-1 has been implicated in the re-
gulation of asymmetric neuroblast divisions involving
neural lineages that divide during embryogenesis until
the first larval stage [12]. These neuroblast divisions gen-
erate one smaller, anterior offspring fated to undergo
apoptosis, and one larger, posterior offspring fated to be-
come a neural precursor. Mutations of the gm280, gm300,
and gm301 alleles of PIG-1 result in a higher penetrance
of neurons due to an abnormal, centrally-located mitotic
spindle. This mutation yields two neuronal precursors ra-
ther than one, resulting in a subsequent increase in the
number of neuroblast cells. PIG-1 is localized to centro-
somes in dividing neuroblasts independently of its kinase
activity, but the function of this centrosomal localized
PIG-1 remains unknown [42]. Mechanistically, the regula-
tion of asymmetric neuroblast divisions by PIG-1 is con-
trolled by the phosphorylation of the conserved Thr169
in its activation loop by PAR-4 (the LKB1 homolog in
C. elegans). This suggests that PIG-1/MELK may be
regulated by upstream kinases in vivo. Thus, PIG-1 in
C. elegans may contribute to determine the daughter
cell fates in neuroblasts.
In contrast to these studies describing the positive
roles of PIG-1 in cell division, Denning et. al [21] demon-
strated that PIG-1 may also promote cell death through a
caspase-independent cell extrusion mechanism. The pro-
posed role for PIG-1 is the prevention of cell surface
expression of cell-adhesion molecules. This results in
detachment and subsequent cell death of the shed cell.
Remarkably, this process is also dependent on the PAR-4
kinase complex, indicating the significance of the PAR-4/
PIG-1 signaling axis in C. elegans.
MELK in zebra fish hematopoiesis
A MELK-like gene (zMELK) was identified in zebra fish
(Danio rerio) based upon high homology of the kinase,
UBA, and KA1 domain with mouse and human MELK
[13]. Additionaly, zMELK and human MELK genes are
preferentially expressed in embryonic brains and retinas,
especially in the proliferative ventricular zones, where
neural stem cells are localized. In the adult zebra fish
however, zMELK expression is limited to a subset of he-
matopoietic tissues [43]. zMELK likely plays an essential
role in organogenesis, as disrupted zMELK expression
by Morpholino injection resulted in numerous develop-
mental abnormalities including severe anemia, retarded
eye development, a swollen cerebral tectum, and a slower
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abnormalities largely remain undetermined. The devel-
opment of severe anemia induced by Morpholino in-
jection suggests that zMELK is essential for primitive
hematopoiesis. Nonetheless, the overall phenotype of
zMELK knockdown in zebra fish embryos is rather sub-
tle, unlike the results by introducing MELK mutation in
Xenopus and C. elegans. These phenotypic differences
may arise from structural, regulatory, or signaling differ-
ences of zMELK compared to other MELK orthologs.
MELK in Xenopus laevis embryogenesis
In Xenopus laevis, the MELK ortholog pEg3 or xMELK
shows the same domain structure as human MELK
(Figure 1) except for the lack of the leucine zipper as
in zMELK. xMELK is critical for proper cell division,
and furthermore, altering xMELK expression either by
knockdown or overexpression leads to abortive cell di-
visions in Xenopus embryos. This indicates that tight
control of xMELK expression during the cell cycle is
critical [14,44]. As the cell prepares to enter mitosis,
xMELK protein is diffusely distributed in the cytoplasm
at interphase, however, during anaphase and telophase,
xMELK is associated with the cleavage furrow of divid-
ing cells. This pattern of expression indicates MELK is
likely involved with proper completion of cell division
[14]. The distribution of MELK in the cell during these
phases of the cell cycle are displayed in Figure 3.Figure 3 This schematic illustrates the various developmental functio
represents a nuclear envelope.Overall, non-mammalian MELK has several unique
functions in individual organisms mostly related to cell
division and daughter cell fates. MELK regulates asym-
metric cell division and apoptotic cell death in C. ele-
gans, hematopoiesis in zebra fish, and cytokinesis in
Xenopus. Though the theme of cell division is common
among the MELK orthologs, each has a unique function.
These differences may be due to slight variations of se-
quence and domains, organ-specific expression patterns,
and molecular interactions. Further studies are needed
to understand the specific functions of MELK in each
system.
Conclusion
In a variety of systems and organisms, MELK appears to
be highly conserved with a significant effect on prolife-
ration, cell cycle regulation, and apoptosis. Aberrant
regulation and activity of MELK is implicated in a var-
iety of human cancers predominantly because of these
properties, but also possibly because of its effect on can-
cer stem cells. In addition, inhibiting MELK may have
potential therapeutic value as preliminary studies with
the use of knockdown strategies and small molecule inhib-
itors have revealed promising results in vitro and in vivo.
Although there appears to be a broad spectrum of func-
tions for MELK, detailed mechanisms with upstream and
downstream signaling pathways still need to be identified.
In addition, several lines of research demonstrate thatns of MELK. MELK expression is represented by red coloring. Blue
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effects. This dual functionality appears to be dependent
on biological context and the system being studied, and
more research in this area is required to identify these
variables. Various nonmammalian species represent im-
portant systems in which to study these variables. Ad-
ditional studies will have an exciting impact on our
understanding of MELK and its effect on development
and disease.
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